Gilead and PAHO agree to expedite lenacapavir access for HIV prevention

Gilead Sciences and the PAHO have signed an agreement to expedite access to the company’s twice-yearly lenacapavir injection for HIV prevention as PrEP across Latin America and the Caribbean.